Takeda Pharmaceutical (NYSE:TAK) Upgraded to “Strong-Buy” at Wall Street Zen

Takeda Pharmaceutical (NYSE:TAK) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also issued reports about the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Morgan Stanley initiated coverage on shares of Takeda Pharmaceutical in a report on Tuesday, January 13th. They set an “overweight” rating on the stock. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock opened at $17.21 on Friday. The company has a current ratio of 1.37, a quick ratio of 0.76 and a debt-to-equity ratio of 0.61. The stock has a 50 day simple moving average of $15.41 and a 200-day simple moving average of $14.81. The company has a market cap of $54.76 billion, a price-to-earnings ratio of 71.71 and a beta of 0.03. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $17.25.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.44 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.44. The firm had revenue of $7.30 billion for the quarter, compared to analyst estimates of $8.01 billion. Takeda Pharmaceutical had a return on equity of 10.73% and a net margin of 2.58%. On average, equities analysts forecast that Takeda Pharmaceutical will post 1.64 EPS for the current year.

Institutional Trading of Takeda Pharmaceutical

Several large investors have recently modified their holdings of TAK. Franklin Resources Inc. increased its stake in Takeda Pharmaceutical by 3.8% in the third quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock valued at $285,000 after purchasing an additional 713 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Takeda Pharmaceutical by 3.3% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 22,088 shares of the company’s stock worth $341,000 after buying an additional 715 shares during the last quarter. Private Trust Co. NA grew its holdings in Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after buying an additional 783 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 5.3% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 16,927 shares of the company’s stock valued at $248,000 after acquiring an additional 850 shares during the last quarter. Finally, Sanctuary Advisors LLC lifted its holdings in shares of Takeda Pharmaceutical by 4.0% during the 4th quarter. Sanctuary Advisors LLC now owns 23,626 shares of the company’s stock worth $368,000 after acquiring an additional 912 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Takeda Pharmaceutical

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Takeda raised FY‑2025 revenue guidance to $29.4 billion and issued EPS guidance of 3.160, above consensus revenue expectations — a clear near‑term positive for top‑line visibility and investor sentiment.
• Positive Sentiment: Q3 results beat expectations: EPS $0.95 vs. $0.55 consensus; management cited cost discipline, FX tailwinds and narrowing gap between Growth & Launch products and VYVANSE generic erosion—management is tightening OPEX and raising confidence in the full‑year outlook. Takeda Reports Third-Quarter FY2025 Results
• Neutral Sentiment: CEO Christophe Weber discussed succession planning and avoiding a ‘lame duck’ exit — governance and leadership continuity themes that reduce execution risk but are longer‑term in impact. Takeda’s Christophe Weber on avoiding a ‘lame duck’ succession
• Neutral Sentiment: Earnings‑call and transcript detail product performance, launch timing and cost actions — useful for modeling but not an immediate catalyst. Takeda Q3 FY2025 Earnings Call Transcript
• Negative Sentiment: Analyst downgrade from Buy to Hold after TAK hit 52‑week highs — valuation noted as less compelling and the lack of a clear Entyvio successor reduces near‑term upside; this can pressure sentiment and limit multiple expansion. Takeda Tests New Highs, But Struggles To Find Entyvio Successor
• Negative Sentiment: Legal exposure: an adverse jury outcome in an Actos-related case and active litigation motions (including efforts to move a Louisiana suit) represent potential liabilities and headline risk that can weigh on the stock. Takeda and Eli Lilly fall foul of jury in Actos Pharma company wants La. suit over stomach acid meds moved

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.